445680 — Curiox BioSystems Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩425bn
- KR₩408bn
- KR₩7bn
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 4,384 | 5,523 | 7,237 | 6,788 |
Cost of Revenue | ||||
Gross Profit | 2,930 | 3,494 | 4,733 | 3,825 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Depreciation and Amortization | ||||
Unusual Expense / Income | ||||
Total Operating Expenses | 7,651 | 13,944 | 18,658 | 17,345 |
Operating Profit | -3,267 | -8,421 | -11,421 | -10,557 |
Gain / Loss on Sale of Assets | ||||
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -6,428 | -14,693 | -11,290 | -10,211 |
Provision for Income Taxes | ||||
Net Income After Taxes | -6,279 | -14,525 | -11,498 | -10,042 |
Minority Interest | ||||
Net Income Before Extraordinary Items | ||||
Net Income | -6,279 | -14,524 | -11,495 | -10,040 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -6,279 | -14,524 | -11,495 | -10,040 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -784 | -1,806 | -1,434 | -1,407 |
Dividends per Share |